| ［1］ |
Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins［J］. Nat Chem Biol, 2008,4（5）:313⁃321. doi: 10.1038/nchembio.83.<br />
|
| ［2］ |
Grootjans S, Vanden BT, Vandenabeele P. Initiation and ution mechanisms of necroptosis: an overview［J］. Cell Death Differ, 2017,24（7）:1184⁃1195. doi: 10.1038/cdd.2017.65.<br />
|
| ［3］ |
Chan FK, Luz NF, Moriwaki K. Programmed necrosis in the cross talk of cell death and inflammation［J］. Annu Rev Immunol, 2015,33:79⁃106. doi: 10.1146/annurev⁃immunol⁃032414⁃112248.<br />
|
| ［4］ |
Tummers B, Green DR. Caspase⁃8: regulating life and death［J］. Immunol Rev, 2017,277（1）:76⁃89. doi: 10.1111/imr.12541.<br />
|
| ［5］ |
Kondylis V, Kumari S, Vlantis K, et al. The interplay of IKK, NF⁃κB and RIPK1 signaling in the regulation of cell death, tissue homeostasis and inflammation［J］. Immunol Rev, 2017,277（1）:113⁃127. doi: 10.1111/imr.12550.<br />
|
| ［6］ |
Vanden BT, Hassannia B, Vandenabeele P. An outline of necrosome triggers［J］. Cell Mol Life Sci, 2016,73（11⁃12）:2137⁃2152. doi: 10.1007/s00018⁃016⁃2189⁃y.<br />
|
| ［7］ |
Onizawa M, Oshima S, Schulze⁃Topphoff U, et al. Erratum: the ubiquitin⁃modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis［J］. Nat Immunol, 2015,16（7）:785. doi: 10.1038/ni0715⁃785c.<br />
|
| ［8］ |
Liu X, Shi F, Li Y, et al. Post⁃translational modifications as key regulators of TNF⁃induced necroptosis［J］. Cell Death Dis, 2016,7（7）:e2293. doi: 10.1038/cddis.2016.197.<br />
|
| ［9］ |
Newton K, Manning G. Necroptosis and inflammation［J］. Annu Rev Biochem, 2016,85:743⁃763. doi: 10.1146/annurev⁃biochem⁃060815⁃014830.<br />
|
| ［10］ |
He S, Huang S, Shen Z. Biomarkers for the detection of necrop⁃tosis［J］. Cell Mol Life Sci, 2016,73（11⁃12）:2177⁃2181. doi: 10. 1007/s00018⁃016⁃2192⁃3.<br />
|
| ［11］ |
Wang H, Sun L, Su L, et al. Mixed lineage kinase domain⁃like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3［J］. Mol Cell, 2014,54（1）:133⁃146. doi: 10.1016/j.molcel.2014.03.003.<br />
|
| ［12］ |
Petrie EJ, Hildebrand JM, Murphy JM. Insane in the membrane: a structural perspective of MLKL function in necroptosis［J］. Immunol Cell Biol, 2017,95（2）:152⁃159. doi: 10.1038/icb.2016. 125.<br />
|
| ［13］ |
Hildebrand JM, Tanzer MC, Lucet IS, et al. Activation of the pseudokinase MLKL unleashes the four⁃helix bundle domain to induce membrane localization and necroptotic cell death［J］. Proc Natl Acad Sci U S A, 2014,111（42）:15072⁃15077. doi: 10. 1073/pnas.1408987111.<br />
|
| ［14］ |
Pacheco FJ, Almaguel FG, Evans W, et al. Docosahexanoic acid antagonizes TNF⁃α⁃induced necroptosis by attenuating oxidative stress, ceramide production, lysosomal dysfunction, and auto⁃phagic features［J］. Inflamm Res, 2014,63（10）:859⁃871. doi: 10. 1007/s00011⁃014⁃0760⁃2.<br />
|
| ［15］ |
Schenk B, Fulda S. Reactive oxygen species regulate Smac mimetic/TNFα⁃induced necroptotic signaling and cell death［J］.Oncogene, 2015,34（47）:5796⁃5806. doi: 10.1038/onc.2015.35.<br />
|
| ［16］ |
Zhang Y, Su SS, Zhao S, et al. RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruit⁃ment into necrosome［J］. Nat Commun, 2017,8:14329. doi: 10.1038/ ncomms14329.<br />
|
| ［17］ |
Kim SK, Kim WJ, Yoon JH, et al. Upregulated RIP3 potentiates MLKL phosphorylation⁃mediated programmed necrosis in toxic epidermal necrolysis［J］. J Invest Dermatol, 2015,135（8）:2021⁃2030. doi: 10.1038/jid.2015.90.<br />
|
| ［18］ |
Paquet P, Jennes S, Rousseau AF, et al. Effect of N⁃acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof⁃of⁃concept study［J］. Burns, 2014,40（8）:1707⁃1712. doi: 10.1016/ j.burns.2014.01.027.<br />
|
| ［19］ |
Weinlich R, Oberst A, Dillon CP, et al. Protective roles for caspase⁃8 and cFLIP in adult homeostasis［J］. Cell Rep, 2013,5（2）:340⁃348. doi: 10.1016/j.celrep.2013.08.045.<br />
|
| ［20］ |
Bonnet MC, Preukschat D, Welz PS, et al. The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation［J］. Immunity, 2011,35（4）:572⁃582. doi: 10.1016/j.immuni.2011.08.014.<br />
|
| ［21］ |
Boehncke WH, Schön MP. Psoriasis［J］. Lancet, 2015,386（9997）:983⁃994. doi: 10.1016/S0140⁃6736（14）61909⁃7. <br />
|
| ［22］ |
Kumari S, Pasparakis M. Epithelial cell death and inflammation in skin［J］. Curr Top Microbiol Immunol, 2017,403:77⁃93. doi: 10. 1007/82_2015_466.<br />
|
| ［23］ |
Gru AA, Salavaggione AL. Lichenoid and interface dermatoses［J］. Semin Diagn Pathol, 2017,34（3）:237⁃249. doi: 10.1053/j.semdp. 2017.03.001.<br />
|
| ［24］ |
Lauffer F, Jargosch M, Krause L, et al. Type I immune response induces keratinocyte necroptosis and is associated with interface dermatitis［J］. J Invest Dermatol, 2018. doi: 10.1016/j.jid.2018. 02.034.<br />
|
| ［25］ |
Abe R. Immunological response in Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. J Dermatol, 2015,42（1）:42⁃48. doi: 10.1111/1346⁃8138.12674.<br />
|
| ［26］ |
Saito N, Qiao H, Yanagi T, et al. An annexin A1⁃FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions［J］. Sci Transl Med, 2014,6（245）:245ra95. doi: 10.1126/scitranslmed.3008227.<br />
|
| ［27］ |
Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis［J］. J Am Acad Dermatol, 2014,71（2）:278⁃283. doi: 10.1016/j.jaad.2014.04.044.<br />
|
| ［28］ |
Panayotova⁃Dimitrova D, Feoktistova M, Leverkus M. RIPping the skin apart: necroptosis signaling in toxic epidermal necrolysis［J］. J Invest Dermatol, 2015,135（8）:1940⁃1943. doi: 10.1038/jid.2015.159.<br />
|
| ［29］ |
Paquet P, Jennes S, Rousseau AF, et al. Effect of N⁃acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof⁃of⁃concept study［J］. Burns, 2014,40（8）:1707⁃1712. doi: 10.1016/j.burns.2014.01.027.<br />
|
| ［30］ |
Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF⁃α antagonist in CTL⁃mediated severe cutaneous adverse reactions［J］. J Clin Invest, 2018,128（3）:985⁃996. doi: 10.1172/JCI93349.<br />
|
| ［31］ |
Conrad M, Angeli JP, Vandenabeele P, et al. Regulated necrosis: disease relevance and therapeutic opportunities［J］. Nat Rev Drug Discov, 2016,15（5）:348⁃366. doi: 10.1038/nrd.2015.6.<br />
|
